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Purpose:  To  describe  the  CT  and  MRI  appearances  of  papillary  renal  cell  carcinoma.
Materials and  methods:  Retrospective  study  of  102  papillary  carcinomas  in  79  patients,  81
tumors examined  by  CT  and  56  by  MRI.  Tumor  size,  homogeneity  and  contrast  enhancement
were recorded.
Results:  The  most  common  presentation  of  papillary  renal  cell  carcinoma  was  a  small  homoge-
neous hypovascular  tumor  both  on  CT  and  MRI.  Eighty-nine  percent  of  lesions  were  hypointense
on T2  weighted  images  compared  to  the  renal  parenchyma.  Seventeen  percent  of  the  lesions
did not  signiﬁcantly  enhance  with  contrast  on  CT.  All  of  the  lesions  examined  on  MRI  had  a
signiﬁcant enhancement  percentage.  Calciﬁcations  were  rare  and  only  seen  in  7%  of  cases  (CT).
The second  most  common  presentation  was  a  bulky  necrotic  tumor.  In  addition,  atypical  types
of disease  were  found  which  were  difﬁcult  to  diagnose,  including  inﬁltrating  tumors  and  tumors
with a  fatty  component.
Conclusion:  A  homogeneous  hypovascular  renal  tumor  which  is  hypointense  on  T2  weighted
images should  suggest  a  diagnosis  of  papillary  carcinoma.  Some  papillary  carcinomas  do  not
enhance  signiﬁcantly  on  CT.  MRI  
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apillary  carcinoma  (PC)  accounts  for  10  to  15%  of  renal
ell  carcinomas  [1].  There  have  been  many  difﬁculties  over
everal  years  in  classifying  this  tumor  according  to  its  histo-
ogical  and  cytogenetic  features  [1]  (classiﬁcation  into  types
 and  2  [2,3],  carcinomas  with  MITF/TFE  translocations,
ubulomucinous  carcinomas,  etc.).  Its  prognosis  compared
o  clear  cell  carcinoma  (CCC)  has  been  extensively  debated:
he  ‘‘conventional’’  assumption  that  PC  carries  a  better
rognosis  [4—7]  has  been  contested,  as  studies  [8,9]  on
arge  series  have  concluded  that  both  histological  subtypes
arry  a  similar  prognosis  for  the  same  stage  and  grade.
ecause  papillary  carcinomas  are  often  multifocal  and  bilat-
ral,  their  preoperative  diagnosis  is  important  and  may  lead
o  treatment  to  preserve  the  kidney,  particularly  as  the
urrent  indications  for  partial  nephrectomy  are  widening
nd  percutaneous  ablation  techniques  (radiofrequency  and
ryoablation)  are  increasingly  being  used.
Current  ﬁndings  reported  in  the  literature  suggest  that
he  tumor  is  often  hypovascular  on  computed  tomography
CT)  [10]  and  MRI  [11],  and  is  hypointense  on  T2  weighted
maging  [11].  We  have  reviewed  the  sectional  imaging  of
02  tumors  in  order  to  examine  the  most  typical  features
f  papillary  renal  cell  carcinoma  and  to  identify  misleading
ppearances  which  can  lead  to  diagnostic  errors.
aterials and methods
tudy population
he  patients  were  selected  from  pathological  anatomy  and
adiological  databases.
We  searched  for  any  CT  and  MRI  investigations  per-
ormed  before  surgery  or  biopsy.  The  investigations  had  to
e  available  on  the  imaging  system  (Picture  Archiving  and
ommunication  System  [PACS])  in  order  to  enable  the  var-
ous  measurements  to  be  performed  (investigations  which
ere  only  available  on  ﬁlm  were  not  included).  Only  tumors
t  least  10  mm  in  size  were  considered  (microlesions  under
0  mm  in  size  were  excluded  in  order  to  avoid  partial  volume
ffects  when  density  and  signal  measurements  were  made
nd  the  stiffening  effect  of  the  CT  beam  [12]).
Pathological  anatomy  examination  (surgical  specimen  or
iopsy)  was  available  for  each  patient  and  included  both
 macroscopic  examination  (for  surgical  specimens)  and
istology  (hematoxylin-eosin-safran  staining).  Immunohis-
ochemistry  (in  particular,  anti-cytokeratin  7  antibodies,
imentin,  racemase  and  CD  10)  were  performed  on  some
umors.
One  hundred  and  two  papillary  carcinomas  were  found
ver  a  period  of  6  years  (between  2002  and  2008)  in  79
atients  (60  men,  19  women,  sex  ratio  =  3.2).  The  average
ge  of  the  patients  was  61  years  old  (with  a  range  of  18  to
4  years  old).
T techniquee  found  81  tumors  which  were  investigated  by  computed
omography  using  a  4-stage  protocol  in  75%  of  cases  (61
atients):  unenhanced,  and  then  in  the  arterial  phase  (30C.  Couvidat  et  al.
o  40  seconds  after  beginning  the  iodine  contrast  injec-
ion),  tubular  phase  (90  to  120  seconds)  and  delayed  phase
between  3 and  6  minutes),  on  a  4  detector  helicoidal
achine,  Philips  Mx  8000  (Marconi  Medical  System).  All
ut  two  of  the  remaining  25%  of  patients  had  a  3-stage
T  investigation  (involving  helicoidal  acquisition  without
nhancement  and  then  in  the  arterial  and  delayed  phases),
erformed  on  an  Aquilion  16  detector  helicoidal  machine
Toshiba).
The  contrast  medium  used  was  Xénétix  350,  injected
ntravenously  into  the  brachial  vein  in  the  antecubital  fossa
120  to  140  mL,  not  exceeding  2  mL/kg  patient  body  weight;
njections  rate:  2.5  to  3.5  mL/s).  The  following  features
ere  recorded  for  each  lesion:
topography:  number  of  tumors,  site,  size  (2  perpendicular
measurements  in  the  axial  plane);
morphology:  encapsulated  appearance  (a  tumor  with
well  demarcated  boundaries  deforming  the  contour  of
the  kidney  with  a  mass  effect  on  adjacent  structures)
or  inﬁltrating  (poorly  demarcated  tumor  boundaries  not
deforming  the  outline  of  the  kidney  but  occasionally
increasing  its  volume  with  invasion  of  adjacent  struc-
tures);  calciﬁcations;  fatty  component  (density  less  than
−20  HU)  within  the  tumor;  homogeneity  after  iodine  con-
trast  enhancement;
measurement  of  density:  density  in  Hounsﬁeld  units  (HU)
before  the  injection  and  in  the  different  stages:  maximum
enhancement  (maximum  density  −  density  before  injec-
tion);  acquisition  time  at  which  the  enhancement  was
maximal;
locoregional  extension:  invasion  of  the  renal  vein;
enlarged  lymph  nodes.
RI technique
e  found  56  tumors  examined  by  MRI  (Genesis  Signal  HD
.5  T  machine,  General  Electric  Healthcare)  in  38  patients.
he  protocol  involved  a  single  plane,  usually  axial  (and  occa-
ionally  coronal,  depending  on  the  site  of  the  lesion),  T2
eighted  images  with  fat  suppression  (Fat  Sat)  (RT:  6,000  to
,000  ms;  ET:  90  to  106  ms),  T1  weighted  images  (RT:  165  to
00  ms;  ET:  1.5  to  1.9  ms)  and  a  T1  weighted  3D  EG  ultrara-
id  dynamic  image  before  and  after  injection  of  gadolinium
helate  (Dotarem,  0.2  mL/kg  patient  body  weight,  2  mL/s)
n  the  arterial  phase  (30  seconds  after  beginning  the  injec-
ion),  tubular  phase  (90  seconds)  and  delayed  phase  (3  to
 minutes  with  a  sequence  at  10  minutes  in  some  cases).  In
hase  and  out  of  phase  images  (IP/OP)  were  also  available  in
4%  of  patients  (19  of  56  tumors).  The  following  MRI  features
ere  examined:
topography:  number  of  tumors;  site;  size  (two  perpendic-
ular  measurements);
morphology:  encapsulated  or  inﬁltrated  appearance;
tumor  appearance  on  T1  and  T2  Fat  Sat  weighted  images
compared  to  the  adjacent  renal  parenchyma;  homogene-
ity;  qualitative  comparison  of  tumor  image  between  in
phase  and  out  of  phase  images;
examination  of  contrast  enhancement:  measurement  of
the  tumor  image  on  the  dynamic  sequence  in  the  dif-
ferent  phases;  calculation  of  percentage  enhancement
((max  signal  −  signal  without  enhancement)/signal  with-
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it  was  over  15%  [13]  and  the  acquisition  time  at  which  the
enhancement  was  maximal;
• locoregional  extension:  invasion  of  the  renal  vein;
enlarged  lymph  nodes.
Thirty-ﬁve  tumors  were  studied  using  both  methods.
The  regions  of  interest  (ROI)  were  identiﬁed  both  on  CT
and  on  MRI:
• for  homogeneous  lesions:  in  the  central  part  of  the  tumor;
• for  cystic/necrotic  lesions:  in  the  tissue  part  of  the
portion  of  the  lesion  if  this  was  of  sufﬁcient  size.
The  ROI  were  identical  in  size  and  position  in  all  phases.
Results
Topography
Seven  patients  (9%)  had  multiple  tumors,  including  2  (2.5%)
who  had  bilateral  tumors.  The  tumor  was  located  in  the  right
kidney  in  53%  of  cases  and  in  the  left  kidney  in  47%  of  cases.
In  4%  of  cases,  the  tumor  had  developed  in  the  patient’s
natural  kidney  in  a  renal  transplant  patient.
CTMorphology
The  tumors  were  encapsulated  in  98%  of  cases.  Two  tumors
were  inﬁltrating.





Figure 1. Small clearly demarcated, homogenous tumor enhancing we
(33 HU); b: arterial phase (38 HU); c: tubular phase (62 HU); d: delayed p1057
The  lesions  were  homogeneous  in  85%  of  cases  and  had  an
verage  size  of  2.4  cm  (from  1.0  to  7.7  cm)  (Fig.  1)  compared
o  an  average  size  of  10.1  cm  (from  6.8  to  18.4  cm)  in  the
5%  of  tumors  which  had  heterogeneous  enhancement  and
ontained  a  cystic  or  necrotic  proportion  (Fig.  2).  Six  tumors
7%  of  tumors  examined  on  CT)  contained  calciﬁcations.  Half
f  these  were  peripheral  and  linear  and  half  were  rounded
n  appearance  (Fig.  3).
One  tumor  contained  a  fatty  density  (density  less  than
20  HU),  because  of  bone  metaplasia  (Fig.  4).  This  tumor
lso  contained  calciﬁcations.  These  ﬁndings  are  summarized
n  Table  1.
ensity  and  contrast  enhancement
ean  tumor  density  before  enhancement  was  35  HU  (from
0  to  62  HU).
It  was  not  possible  to  calculate  the  maximum  enhance-
ent  in  two  cases  as  there  was  no  unenhanced  phase.  The
ercentages  below  were  therefore  calculated  from  a  total
f  79  tumors.
The  distribution  of  maximum  enhancement  values  is
hown  in  Fig.  5.
Variation  in  density  was  indeterminate  in  16.5%  of  cases
between  10  and  15  HU)  or  negative  (less  than  10  HU)  in  5%
f  cases.  These  were  small  lesions  (on  average  29  mm  along
heir  long  axis,  with  a  range  of  12  to  43  mm)  which  were
omogeneous  and  not  calciﬁed  (Fig.  6).  Their  average  den-
ity  before  enhancement  was  31  HU,  with  a  range  of  10  to
5  HU.  In  two  cases  the  unenhanced  density  was  less  than
akly: typical CT appearance of papillary carcinoma; a: unenhanced
hase (66 HU).
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Figure 2. Massively necrotic heterogeneous papillary carcinoma. CT: a
































0  HU.  The  maximum  contrast  enhancement  in  these  two
esions  was  14  and  15  HU,  respectively.
Maximum  enhancement  was  less  than  40  HU  in  82%  of
ases.
If  only  the  small  tumors  under  3  cm  in  size  were  con-
idered,  100%  of  lesions  were  homogeneous  and  average
aximum  contrast  enhancement  was  35  HU  (from  13  to
1  HU).The  time  to  maximum  enhancement  was  recorded  for  the
umors  which  were  examined  using  a  4-phase  protocol.  This
(
n
igure 4. Papillary carcinoma containing an area of fatty density combi
agniﬁcation × 4. Area of bone metaplasia calciﬁed in placed represen
taining magniﬁcation × 20. Tumor of papillary architecture with foamy : before enhancement; b: arterial phase; c: tubular phase.
as  during  the  tubular  phase  in  67%,  followed  by  the  delayed
hase  (22%)  and  arterial  phase  (11%)  (Fig.  7).
ocoregional  invasion
he  two  inﬁltrating  tumors  were  associated  with  renal  vein
nvasion.  There  were  also  necrotic  enlarged  retroperitoneal
ymph  nodes  (peri-hilar  and  inter-aorta-caval  regions)  in  one
ase  (Fig.  8),  which  was  a  sarcomatoid  form  of  papillary
arcinoma  (Fuhrman  high  grade).
RI
orphology
he  T2  weighted  tumor  signal  was  homogeneous  in  57%  of
ases,  slightly  heterogeneous  in  9%  and  heterogeneous  in
4%.
Eighty-nine  percent  of  tumors  were  hypointense  com-
ared  to  the  normal  renal  parenchyma  on  T2  weighted
mages  (Fig.  9),  9%  were  hyperintense  and  2%  were  isoin-
ense.
Tumors  under  3  cm  in  size  (48%)  were  all  hypointense  on
2  weighted  images.
The  tumor  signal  was  more  variable  on  T1  weighted
mages:  50%  were  isointense,  32%  were  hypointense  and  18%IP/OP)  sequences,  47%  (9/19)  had  a  lower  in  phase  sig-
al  intensity  than  out  of  phase.  This  was  diffuse  in  6  cases
ned with calciﬁcations; a: unenhanced CT; b: histology: HES staining
ting the macroscopic area of fat seen on the CT; c: histology: HES
macrophages along the axes bordered by a layer of tumor cells.
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Table  1  Topographic,  morphological  and  locoregional
extension  features  on  CT  and  MRI.
Features  Number  of  tumors
involved  (percentage)
Topography
Multiple  tumors 7  patients  (9%)
Bilateral  tumors 2  patients  (2.5%)
Type  of  tumor
Encapsulated  100  (98%)
Inﬁltrating  2  (2%)
CT  features
Homogeneous  (mean  size:
2.4  cm)
69 (85%)
Heterogeneous  (mean  size:
10.1  cm)
12  (15%)
Calciﬁcations  6  (7%)
Macroscopic  fatty  component  1  (1%)
MRI  features
T2
Homogeneous  32  (57%)
Slightly  heterogeneous  19  (34%)
Heterogeneous  5  (9%)
T2
Hypointense  50  (89%)
Isointense  1  (2%)
Hyperintense  5  (9%)
T1
Hypointense  18  (32%)
Isointense  28  (50%)
Hyperintense  10  (18%)
IP/OP
Increased  in  out 9/19  (47%)
Fall  in  out 3/19  (16%)
No  change 7/19  (37%)
Locoregional  extension
Invasion  of  veins  2  (2%)
Enlarged  lymph  nodes  1  (1%)
Figure 5. Histogram showing the distribution of maximum con-

















































Fig.  10)  and  focal  in  the  other  3  cases.  In  three  tumors
16%),  the  signal  intensity  was  lower  on  the  out  of  phase
equence.
These  ﬁndings  are  summarized  in  Table  1.
tudy  of  contrast  enhancement
he  average  contrast  enhancement  percentage,  which  was
eﬁned  as  signiﬁcant  over  15%  [13], was  68%  (range  from  16
o  278%).  All  of  the  tumors  enhanced  signiﬁcantly.  Contrast
nhancement  was  80%  or  less  in  78%  of  cases.
Nine  of  the  13  tumors  which  did  not  enhance  signiﬁcantly
n  CT  were  examined  by  MRI.  All  of  these  enhanced  signiﬁ-
antly  with  an  average  contrast  enhancement  of  48%  (from
5  to  74%).
Mean  contrast  enhancement  in  the  tumors  under  3  cm  in
ize  was  69%  (from  20  to  172%).
The  distribution  of  maximum  enhancement  times  was
imilar  to  what  was  found  on  CT  (Fig.  7):  60%  of  tumors
xhibited  maximum  enhancement  on  the  tubular  phase,  30%
n  the  delayed  phase  and  10%  on  the  arterial  phase.
ocoregional  invasion
ne  inﬁltrating  tumor  was  associated  with  invasion  of  the
enal  vein  and  enlarged  necrotic  lymph  nodes  (the  sarco-
atoid  form  of  papillary  carcinoma  which  was  examined  on
oth  CT  and  MRI).
iscussion
he  histological  classiﬁcation  of  renal  cell  carcinomas  is
ased  on  histological,  immunohistochemical  and  cytoge-
etic  features.
Several  studies  have  been  carried  out  in  order  to  distin-
uish  histological  types  on  CT  [14,15]  and  MRI  [11,16].
The  ‘‘encapsulated  form’’,  i.e.  tumors  with  well  demar-
ated  boundaries  deforming  the  contours  of  the  kidney
nd  pushing  back  adjacent  structures,  made  up  98%  of  the
umors  in  our  series.  Inﬁltrating  tumors  are  rare  amongst
he  papillary  carcinomas  and  in  the  ‘‘common’’  renal  cell
arcinomas  in  general  (clear  cell,  papillary  and  chromo-
hobe  cell  carcinomas)  where  they  usually  represent  high
uhrman  grade  and  more  aggressive  sarcomatoid  tumors
17]. The  inﬁltrating  lesions  are  usually  due  to  urothe-
ial  carcinomas  of  the  pyelocaliceal  cavities,  hemopathies
lymphomas  or  leukemias),  rare  renal  cell  carcinomas  (col-
ecting  duct  carcinomas,  renal  medullary  carcinomas)  or
nﬂammatory  lesions  (xanthogranulomatous  pyelonephritis
r  malakoplakia)  [18—20].
Only  7%  of  the  lesions  in  our  series  contained  calciﬁca-
ions.  This  is  less  than  is  reported  in  the  literature,  which
escribes  23%  [15]  or  even  32%  [14]  of  PC  as  being  calci-
ed.  These  ﬁgures  are  possibly  overestimated  as  the  series
nvolved  small  numbers  of  tumors  (26  and  19  PC  respec-
ively).
One  tumor  contained  an  area  of  fatty  density,  i.e.  a  den-
ity  of  less  than  −20  HU  on  the  unenhanced  image,  because
f  bony  metaplasia.  The  presence  of  a  macroscopic  fatty
omponent  in  a  renal  mass  should  suggest  the  diagnosis  of
ngiomyolipoma  (AML),  a  benign  tumor  which,  depending  on
ts  size,  requires  surveillance  or  treatment  (embolization  or
1060  C.  Couvidat  et  al.
Figure 6. Papillary carcinoma without enhancement (7 HU difference between the tubular phase and pre-enhancement image), exhibiting
signiﬁcant contrast enhancement on MRI (36% enhancement); a: unenhan
phase; e: MRI: T1 weighted image without enhancement; f: MRI: T1 weig
surgery).  The  case  described  in  our  series  also  contained  cal-
ciﬁcations.  The  diagnosis  of  AML  should  be  reconsidered  if
calciﬁcations  are  combined  with  an  area  of  fatty  density  in  a
renal  tumor,  as  calciﬁed  AML  are  extremely  rare  [21]. Con-
versely,  malignant  tumors  (including  papillary  carcinomas)
containing  macroscopic  fat  are  described  in  the  literature
[22—24].  There  are  four  possible  mechanisms  to  explain  this:
bony  metaplasia  (with  islets  of  fatty  bone  marrow),  massive
necrosis  with  the  formation  of  amalgams  of  lipids  from  cells,
Figure 7. Histogram showing the distribution of maximum con-
trast enhancement by investigation time on CT (for tumors


























dced CT; b: CT: arterial phase; c: CT; tubular phase; d: CT: delayed
hted image in the delayed phase.
holesterol  necrosis  and  ‘‘trapping’’  of  perirenal  fat  or  fat
nside  the  sinuses  [23].
Cases  of  renal  cell  carcinoma  containing  fat  without
oncomitant  calciﬁcations  have  been  described  in  the  lit-
rature  [25]. It  is  far  more  difﬁcult  to  diagnose  a  malignant
umor  in  these  situations,  although  some  signs  do  suggest
alignancy,  including  a  bulky  tumor  with  irregular  outlines
nvading  the  perirenal  or  sinus  fat,  a  bulky  necrotic  tumor
ontaining  small  areas  of  fat  or  signs  of  malignancy,  such  as
nvasion  of  veins  or  enlarged  lymph  nodes  [24].
One  of  these  mechanisms,  cholesterol  necrosis,  is  spe-
iﬁc  to  PC  as  one  of  the  histological  features  of  PC  is  that  it
ontains  foamy  macrophages  located  along  the  axis  of  the
apillae.  If  these  macrophages  are  saturated  with  choles-
erol  crystals  they  may  become  necrotic  and  extracellular
holesterol  deposits  develop.  The  signs  which  suggest  PC
ith  cholesterol  necrosis  in  a  tumor  containing  a  macro-
copic  area  of  fat  but  no  calciﬁcations  are  a  bulky  tumor
ith  low  (tumor/healthy  parenchyma  ratio  less  than  25%  in
he  arterial  phase)  but  homogeneous  enhancement  (except
n  the  areas  of  fat)  [22].
In  16.5%  of  tumors,  there  is  no  signiﬁcant  enhancement
n  CT  (less  than  15  HU)  and  this  may  lead  to  a  tumor  being
issed.  The  tumor  density  before  enhancement  should  alert
he  radiologist  to  the  diagnosis.
With  only  two  exceptions,  all  of  these  lesions  were  ofon-liquid  density  (over  20  HU)  before  enhancement  and
herefore  did  not  meet  the  diagnostic  criteria  for  a  simple
yst  (type  1  of  the  Bosniak  classiﬁcation  [26]).  They  also
id  not  meet  the  diagnostic  criteria  of  a  type  2  cyst  (high
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Figure 8. Inﬁltrating, sarcomatoid, papillary carcinoma with invasion of the renal vein and enlarged necrotic retroperitoneal lymph nodes;
a: CT: tubular phase; b: MRI: T2 weighted image.
Figure 9. Typical MRI appearance of a papillary carcinoma: small homogeneous, well demarcated tumor, hypointense on T2 weighted
image, enhancing weakly (65%) but signiﬁcantly; a: MRI: T2 weighted image; b: MRI: unenhanced T1 weighted image; c: MRI: T1 weighted
image, arterial phase; d: MRI: T1 weighted image, tubular phase.





























































































ttenuation  cyst)  as  their  pre-enhancement  density  was  less
han  50  HU.  These  were  therefore  isodense  renal  parenchy-
al  lesions  which  did  not  take  up  the  contrast  signiﬁcantly
n  CT  and  cannot  therefore  be  diagnosed  by  CT  and  require
RI.  The  two  lesions  with  a  density  of  less  than  20  HU  before
nhancement  (and  which  were  therefore  ‘‘pseudo-liquid’’),
hanged  in  density  by  14  and  15  HU  respectively.  The  change
n  density  after  enhancement  was  therefore  indeterminate
nd  required  MRI  to  distinguish  a  cyst  (which  may  be  sim-
le,  protein  rich  or  hemorrhagic)  from  a  hypovascular  tumor
27].
When  Bosniak’s  criteria  are  used  to  deﬁne  whether  con-
rast  enhancement  is  present  [28],  24%  of  lesions  had
egative  (0  to  10  HU:  6%  of  tumors)  or  equivocal  contrast
ptake  (10  to  20  HU:  18%).
The  lack  of  signiﬁcant  contrast  enhancement  on  CT  may
e  related  to  the  histological  type  of  tumor  as  10  (77%)  of
he  13  tumors  (16.5%)  which  did  not  signiﬁcantly  enhance  on
T  were  type  1  PC.  In  addition,  8  of  these  tumors  had  been
xamined  using  a  4-phase  protocol  (without  enhancement,
rterial,  tubular  and  delayed)  and  maximum  enhancement
as  found  in  the  tubular  phase  in  all  of  these  cases.  This  does
ot  support  the  hypothesis  that  a  later  acquisition  (after
 minutes)  can  identify  a  signiﬁcant  contrast  enhancement.
As  the  activities  at  the  Necker  Hospital  are  focused  on
rological  oncology,  our  study  may  suffer  from  recruitment
ias,  with  a  larger  number  of  tumors  which  have  an  atypical
r  difﬁcult  radiological  presentation.  This  may  partly  explain
he  large  number  of  tumors  which  did  not  take  up  contrast  in
T,  some  of  which  were  incorrectly  reported  as  cystic  lesions
n  previous  investigations.
Ninety-seven  percent  of  tumors  enhanced  in  the  arterial
hase  below  the  cut  off  of  84  HU.  This  is  consistent  with  the
tudy  report  by  Kim  et  al.  [14]  designed  to  distinguish  clear
ell  carcinomas  from  other  histological  types  of  tumor.
One  of  the  weaknesses  of  our  series  is  that  because  it
as  retrospective,  there  was  a  degree  of  variation  in  the
umber  of  CT  acquisitions  in  our  cases  (from  two  to  four)  and
n  the  contrast  medium  used  (osmolality,  amount,  ﬂow  rate)
hich  are  technical  parameters  that  inﬂuence  the  measured
ensities  [29].
On  MRI,  the  papillary  carcinoma  was  hypointense  on  T2
eighted  images  in  89%  of  cases  which  is  consistent  with
ndings  published  in  the  literature  [11,30].
Papillary  carcinoma  also  appears  as  a  hypovascular  tumor
ith  a  mean  enhancement  percentage  of  68  and  69%  for
umors  under  3  cm  in  size,  less  than  the  ﬁgures  reported  by
oy  et  al.  [11]  (120%  in  a  series  of  55  papillary  carcinomas
nder  3 cm  in  size)  and  by  Sun  et  al.  [16]  (from  93  to  113%
epending  on  Furhman  grade,  on  28  papillary  carcinomas).
MRI  is  more  sensitive  on  contrast  enhancement  than  CT.
ine  of  the  13  tumors  which  did  not  signiﬁcantly  enhance
ith  contrast  on  CT  were  also  examined  by  MRI  and  in  100%
f  these  cases  contrast  enhancement  was  signiﬁcant.  MRI  is
herefore  indicated  if  any  doubt  remains  about  the  type  of
issue  involved  in  the  renal  lesion  on  CT.
Ninety-one  percent  of  the  lesions  met  the  diagnostic
riteria  deﬁned  by  Sun  et  al.  [16]  for  the  differential  diagno-
is  between  papillary  carcinoma  and  clear  cell  carcinoma,
.e.  arterial  phase  enhancement  of  less  than  84%  on  MRI.
Increased  signal  on  an  out  of  phase  image  compared  to
he  in  phase  image  may  be  an  additional  diagnostic  featureC.  Couvidat  et  al.
upporting  papillary  carcinoma  on  MRI.  This  was  present  in
7%  (9/19)  of  lesions  in  our  series  and  was  reported  in  44%
f  papillary  carcinomas  compared  to  14%  of  clear  cell  car-
inomas  in  a  study  on  9 papillary  carcinomas  and  57  clear
ell  carcinomas  [31].  The  increased  signal  on  the  out  of
hase  image  may  be  due  to  hemosiderin  within  the  tumor
31], a  common  feature  of  papillary  carcinomas  [32].  One
tudy  published  in  2009  [33]  reported  that  hemosiderin  was
resent  as  commonly  in  papillary  carcinomas  (38%  of  cases)
s  in  clear  cell  carcinomas  (44%).  Further  studies  are  needed
o  conﬁrm  the  diagnostic  value  of  the  hypointensity  on  the
n  phase  image  in  papillary  carcinomas  compared  to  other
istological  types  of  renal  tumors,  particularly  clear  cell
arcinomas.
It  may  be  useful  to  distinguish  between  these  two  histo-
ogical  types  on  imaging  particularly  in  higher  risk  surgery
atients  or  patients  with  a  familial  form  of  papillary  carci-
oma  who  can  be  offered  alternative  treatments  to  surgery
particularly  percutaneous  radiofrequency  ablation).
onclusion
apillary  carcinoma  typically  presented  as  a  small,
omogeneous,  hypovascular,  uncalciﬁed  tumor  which  was
ypointense  on  T2  weighted  sequences  in  our  series.  A
igniﬁcant  proportion  of  tumors  (17%)  did  not  enhance
igniﬁcantly  on  CT.  These  forms  of  tumor  were  usually
f  the  same  density  as  the  adjacent  renal  parenchyma
efore  enhancement  and  should  not  be  interpreted  as  cys-
ic  lesions.  If  any  doubt  remains,  MRI  should  be  performed
s  it  is  more  sensitive  to  contrast  enhancement  (all  of  the
esions  which  did  not  enhance  signiﬁcantly  on  CT  which  were
nvestigated  by  MRI  signiﬁcantly  enhanced  on  a  T1  weighted
ynamic  image  after  gadolinium).
Tumors  which  appear  cystic  or  necrotic  are  not  rare  and  in
his  case  it  is  more  difﬁcult  to  diagnose  a papillary  carcinoma
rom  another  histological  type  of  tumor,  particular  clear  cell
arcinoma  with  a  necrotic  component.
Finally,  atypical  tumors  exist,  which  contain  a  fatty
omponent  or  inﬁltrating  appearance  and  are  difﬁcult  to
iagnose.
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